Insider Selling: Zimmer Biomet Holdings Inc (NYSE:ZBH) Insider Sells 84 Shares of Stock

Zimmer Biomet Holdings Inc (NYSE:ZBH) insider Didier Deltort sold 84 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $140.42, for a total transaction of $11,795.28. Following the completion of the sale, the insider now owns 1,194 shares of the company’s stock, valued at approximately $167,661.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Didier Deltort also recently made the following trade(s):

  • On Friday, September 6th, Didier Deltort sold 360 shares of Zimmer Biomet stock. The shares were sold at an average price of $139.25, for a total transaction of $50,130.00.

Shares of ZBH opened at $140.29 on Thursday. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The stock has a market cap of $28.44 billion, a P/E ratio of 18.36, a PEG ratio of 2.45 and a beta of 1.15. The company has a 50-day moving average of $136.59 and a two-hundred day moving average of $125.34. Zimmer Biomet Holdings Inc has a 12-month low of $96.99 and a 12-month high of $141.75.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.02. The company had revenue of $1.99 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.92 earnings per share. As a group, analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend is Friday, September 27th. Zimmer Biomet’s payout ratio is currently 12.57%.

Large investors have recently bought and sold shares of the company. Private Ocean LLC grew its stake in Zimmer Biomet by 34.8% during the second quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 80 shares during the period. Sound View Wealth Advisors LLC grew its stake in Zimmer Biomet by 2.0% during the first quarter. Sound View Wealth Advisors LLC now owns 4,456 shares of the medical equipment provider’s stock worth $569,000 after buying an additional 87 shares during the period. Charter Trust Co. grew its stake in Zimmer Biomet by 5.5% during the second quarter. Charter Trust Co. now owns 1,793 shares of the medical equipment provider’s stock worth $211,000 after buying an additional 93 shares during the period. Enlightenment Research LLC grew its stake in Zimmer Biomet by 6.7% during the first quarter. Enlightenment Research LLC now owns 1,600 shares of the medical equipment provider’s stock worth $204,000 after buying an additional 100 shares during the period. Finally, Commonwealth Bank of Australia grew its stake in Zimmer Biomet by 0.6% during the first quarter. Commonwealth Bank of Australia now owns 18,199 shares of the medical equipment provider’s stock worth $2,317,000 after buying an additional 100 shares during the period. 89.39% of the stock is owned by institutional investors and hedge funds.

Several analysts recently commented on ZBH shares. Robert W. Baird upgraded shares of Zimmer Biomet from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $132.00 to $154.00 in a research note on Monday, July 29th. TheStreet cut shares of Zimmer Biomet from a “b-” rating to a “c” rating in a research note on Friday, June 7th. Cowen set a $140.00 price objective on shares of Zimmer Biomet and gave the company a “hold” rating in a research note on Friday, July 26th. Barclays upgraded shares of Zimmer Biomet from an “underweight” rating to an “equal weight” rating and raised their price objective for the company from $117.00 to $140.00 in a research note on Tuesday, July 30th. Finally, Credit Suisse Group raised their price objective on shares of Zimmer Biomet from $101.00 to $120.00 and gave the company an “underperform” rating in a research note on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet has an average rating of “Buy” and an average target price of $142.26.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: Limitations to arbitrage trading

Insider Buying and Selling by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.